Dossier assessment
Marstacimab (haemophilia B, with factor IX inhibitors) – Benefit assessment according to §35a Social Code Book V
Report documents
-
Extract of dossier assessment
Marstacimab (haemophilia B, with factor IX inhibitors) – Benefit assessment according to §35a Social Code Book V
-
Dossier assessment
Marstacimab (haemophilia B, with factor IX inhibitors) – Benefit assessment according to §35a Social Code Book V
Dossier assessment
Routine prophylaxis of bleeding episodes in patients 12 years of age and older, weighing at least 35 kg, with haemophilia B (congenital factor IX deficiency) with factor IX inhibitors
Added benefit not proven
Project details
- Project no.
- A26-56
- Commission
- Commission awarded on 01.06.2026 by the Federal Joint Committee (GBA).
- Report type
- Dossier assessment
- Status
- Commission completed
- Department/Division
- Drug Assessment
- Topic
- Haematology
- Note
-
After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.
- DOI
https://doi.org/10.60584/A26-56
Connected Projects
-
Dossier assessment
Marstacimab (haemophilia B) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Marstacimab (haemophilia A) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed
-
Dossier assessment
Marstacimab (haemophilia A, with factor VIII inhibitors) – Benefit assessment according to §35a Social Code Book V
Status: Commission completed